• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

A monoclonal antibody binds to threonine 49 in the non-structural 1 protein of influenza A virus and interferes with its ability to modulate viral rep

tetano

Editor, Senior Moderator
Antiviral Res. 2015 Feb 7;116C:55-61. doi: 10.1016/j.antiviral.2015.01.015. [Epub ahead of print]
[h=1]A monoclonal antibody binds to threonine 49 in the non-structural 1 protein of influenza A virus and interferes with its ability to modulate viral replication.[/h] Barnwal B[SUP]1[/SUP], Mok CK[SUP]1[/SUP], Wu J[SUP]1[/SUP], Diwakar MK[SUP]1[/SUP], Gupta G[SUP]2[/SUP], Zeng Q[SUP]3[/SUP], Chow VT[SUP]1[/SUP], Song J[SUP]2[/SUP], Yuan YA[SUP]4[/SUP], Tan YJ[SUP]5[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] The emergence of resistant influenza A viruses highlights the continuous requirement of new antiviral drugs that can treat the viral infection. Non-structural 1 (NS1) protein, an indispensable component for efficient virus replication, can be used as a potential target for generating new antiviral agents. Here, we study the interaction of 2H6 monoclonal antibody with NS1 protein and also determine whether influenza virus replication can be inhibited by blocking NS1. The 2H6-antigen binding fragment (Fab) forms a multimeric complex with the NS1 RNA-binding domain (RBD). T49, a residue which forms a direct hydrogen bond with double stranded RNA, in NS1 protein was found to be critical for its interaction with 2H6 antibody. NS1(RBD) has high affinity to 2H6 with K[SUB]D[/SUB] of 43.5?4.24nM whereas NS1(RBD)-T49A has more than 250 times lower affinity towards 2H6. Interestingly, the intracellular expression of 2H6-single-chain variable fragment (scFv) in mammalian cells caused a reduction in viral growth and the M1 viral protein level was significantly reduced in 2H6-scFv transfected cells in comparison to vector transfected cells at 12h post infection. These results indicate that the tight binding of 2H6 to NS1 could lead to reduction in viral replication and release of progeny virus. In future, 2H6 antibody in combination with other neutralizing antibodies can be used to increase the potency of viral inhibition.
Copyright ? 2015 Elsevier B.V. All rights reserved.


[h=4]KEYWORDS:[/h] Influenza A virus; Monoclonal antibody; Non-structural 1 protein

PMID: 25666762 [PubMed - as supplied by publisher]
 
Back
Top Bottom